Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82675 | 0.91 | HCAR3 (0.68) | HCAR3PTK2KMT2AHCAR2CYP1A2 | |
| Toluene SCHEMBL9060786 | 0.85 | HCAR3 (0.63) | HCAR3PTK2HCAR2NSD2 | |
| SCHEMBL27347795 | 0.82 | HCAR3 (0.52) | HCAR3PTK2KMT2AHCAR2NSD2 | |
| SCHEMBL27335268 | 0.79 | HCAR3 (0.52) | HCAR3PTK2KMT2AHCAR2NSD2 | |
| Pyridine SCHEMBL2156456 | 0.79 | RAB9A (0.61) | KMT2A | |
| SCHEMBL7093993 | 0.79 | PTK2 (0.62) | HCAR3PTK2KMT2ANSD2CYP1A2 | |
| SCHEMBL27343709 | 0.78 | KDM4E (0.62) | HCAR3PTK2KMT2AHCAR2 | |
| SCHEMBL28118455 | 0.78 | PTK2 (0.54) | HCAR3PTK2KMT2ACYP1A2 | |
| SCHEMBL23488403 | 0.78 | HCAR3 (0.75) | HCAR3KMT2AHCAR2 | |
| SCHEMBL27347169 | 0.77 | HCAR3 (0.55) | HCAR3PTK2KMT2AHCAR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | HCAR3 2878/4885PTK2 3327/4885KMT2A 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.